An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Tavaborole (Primary)
- Indications Onychomycosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 25 Jan 2018 New trial record